Venn Life Sciences Partners With Carrick To Develop Cancer Treatments

LONDON (Alliance News) - Venn Life Sciences Holdings PLC on Friday said it has collaborated with ...

Alliance News 18 January, 2019 | 9:44AM
Email Form

LONDON (Alliance News) - Venn Life Sciences Holdings PLC on Friday said it has collaborated with Carrick Therapeutics Ltd to develop innovative cancer treatments.

The drug development company said Carrick is building a portfolio of first-in-class treatments that target multiple mechanisms of the most aggressive forms of cancer.

Carrick has built a network of partners and collaborators to progress its technology portfolio and Venn will join this network as a provider of early development and clinical research capabilities.

"By linking a network of clinicians and scientists in internationally leading research institutes and hospitals, we will use our multi-asset portfolio to drive the development of these ground-breaking cancer therapies from laboratory to clinic," explained Carrick Chief Executive Elaine Sullivan.

"At Venn we have built a suite of capabilities designed to address all of the development requirements of this model and are delighted to partner with Carrick in the development of their first in class treatments," added Venn Life Chief Executive Tony Richardson.

Venn shares were trading 1.7% lower on Friday at 1.77 pence each.

By Evelina Grecenko; evelinagrecenko@alliancenews.com

Copyright 2019 Alliance News Limited. All Rights Reserved.

Email Form
Securities Mentioned in Article
Security Name Price Change (%) Morningstar Rating
Venn Life Sciences Holdings PLC 6.19 GBX -0.96 -
About Author Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.